SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopifys post-earnings selloff is the main focus, as traders weigh shortfalls in GMV and subscription-related metrics against earnings and cash-flow strength and continued revenue growth. The sharp drop and rebound have split the community between dip buyers calling it an overreaction and bears citing high valuation and moderating growth.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

A record fiscal-quarter earnings beat and raised full-year outlook, supported by strong bookings and AI-chip testing demand, drove AEHRs sharp rally. Traders welcomed the results and AI growth prospects, while others questioned the valuation and whether the rebound can hold.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

MDGL is under pressure despite strong Q3 results and its first profitable quarter, with traders focused on the stocks sharp fade after an initial post-earnings jump. Bulls cite Rezdiffras commercial momentum and room to grow, while skeptics point to slow market penetration, reimbursement hurdles, spending, and the wait for clinical-outcomes data.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs strong quarterly results and raised outlook were met with a selloff, as traders focused on slower contract bookings and the stocks high valuation as potential signs that growth may be harder to sustain. Bulls view the pullback as an overreaction to robust AI demand and commercial momentum, while bears argue the bookings trend leaves future growth uncertain.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckins third-quarter results and a new share repurchase program are driving attention, with traders highlighting stronger profitability and customer growth. The reaction is divided: bulls see improving fundamentals and buybacks as supportive, while skeptics focus on weak same-store sales, stagnant OTC trading, and uncertainty over a U.S. relisting.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transoceans quarterly results and newly released fleet status report are driving discussion, with traders debating the reported GAAP versus adjusted earnings and questioning the sharp share-price decline. Some see longer-term support from contracts and the Valaris merger, while others remain concerned about dilution, debt and weak price action.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiservs quarterly results beat expectations, management reaffirmed its outlook, doubled its cost-savings target and announced plans to resume share repurchases, prompting a sharp rebound after a prolonged selloff. Bulls see a potential turnaround, while skeptics remain focused on execution and margin pressures; short-squeeze talk is speculative.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Attention centers on Candels CAN-2409 prostate-cancer program, with traders watching upcoming clinical data presentations and the planned BLA submission; bullish posters point to the positive Phase 3 results, while skeptics question the regulatory timeline, financing and CEO credibility. The debate is amplified by a sharp share-price decline that some attribute to broader biotech weakness and thin trading, while others see it as company-specific selling pressure.

Backblaze, Inc. operates as a cloud provider for businesses and consumers to store, use, and protect their data. The firm provides a foundation for businesses, developers, IT professionals, and individuals to store, backup, and archive data, host content, manage media, and build their applications. It also offers B2 Cloud Storage and Computer Backup services. The company was founded by Timothy Nufire, Gleb Budman, Charles Jones, Kwok Hang Ng, Brian Wilson, Nilay Patel and Damon Uyeda in 2007 and is headquartered in San Francisco, CA.

Backblaze Inc - Ordinary Shares - Class A

Backblazes stronger-than-expected Q3 results and raised full-year outlook are driving attention, with traders focused on accelerating B2 cloud-storage growth and its potential role in AI infrastructure. The upbeat reaction has been volatile: bulls see evidence the growth story is gaining traction, while skeptics point to slowing retention, declining legacy backup revenue, and post-earnings profit-taking.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Rokus strong Q3 results, with growth in platform and advertising revenue, are drawing attention as shares reach a 52-week high. Traders are weighing the earnings momentum against the pending Fox acquisition, which caps perceived upside and faces added regulatory scrutiny; Roku also withheld its outlook because of the deal.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum

TriSalus Life Sciences Inc. (Nasdaq: TLSI) (TriSalus or the Company), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David...

Verano Holdings Corp. (VRNO) Reports Q3 Loss, Lags Revenue Estimates

Verano Holdings Corp. (VRNO) delivered earnings and revenue surprises of +50.00% and -1.61%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

TriSalus Life Sciences to Host Third Quarter 2026 Financial Results Conference Call

TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the Company), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational immunotherapeutic to transform outcomes for patients with solid tumors, today announced that it will host a conference call and...

TriSalus Secures FDA Clearance For TriNav Advance as Stock Tests Key Support

TriSalus Life Sciences secured FDA clearance for its TriNav Advance device, but shares face critical resistance levels amid a recent slide.read more...

TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday

U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securitize, Lakefront and others also gained.read more...

TriSalus Lands Key FDA Clearance as PEDD Platform Pushes into Tougher Anatomy

TriSalus Life Sciences (NASDAQ:TLSI) cleared a regulatory hurdle that could materially broaden the reach of its Pressure-Enabled Drug Delivery platform.

TriSalus Life Sciences Receives FDA Clearance for TriNav Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery (PEDD) Portfolio for Liver Embolization

TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the Company), an oncology company integrating novel delivery technology with standard-of-care therapies and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced it has received U.S. Food and Drug...

TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference

TriSalus Life Sciences Q2 Earnings Call Highlights

TriSalus Life Sciences Q2 Earnings Call Highlights...

TriSalus Life Sciences Reports Second Quarter 2026 Results

TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the Company), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced financial results for the quarter...

TriSalus Life Sciences, Inc. is an oncology company, which engages in the business of integrating standard-of-care treatments and investigational immunotherapeutic with disruptive pressure enabled drug delivery infusion systems to transform the treatment paradigm for patients battling liver and pancreatic tumors. The company was founded on September 11, 2020 and is headquartered in Westminster, CO.

TriSalus Life Sciences Inc

TriSalus Life Sciences’ Q4 Loss Exceeds Projections, Revenue Tops Estimates – Retail Stays Pessimistic

Equity

Bearish Sentiment

TriSalus Life Sciences Inc. (TLSI) shares were in the spotlight on Thursday morning after the company’s <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.trisaluslifesci.com/news-releases/news-release-details/trisalus-life-sciences-reports-q4-and-full-year-2024-financial">fourth-quarter</a> loss exceeded Wall Street projections, but revenue topped expectations.TriSalus reported a 44% jump in its fourth-quarter (Q4) revenue to $8.3 million, higher than an analyst estimate of $8.25 million, according to FinChat data.The company’s loss per share narrowed to $0.4, compared to $1.57 in the same quarter a year ago, but it was wider than the estimated loss of $0.32.TriSalus reaffirmed its previous guidance for 2025 and said it expects sales growth of over 50% and its gross margin to exceed 87%, higher than the 86% reported for 2024. &nbsp;The oncology-focused medical technology company also said that it expects to be earnings before interest, tax, depreciation, and amortization (EBITDA) positive this year and achieve positive cash flow by the second half, extending its total cash runaway beyond this year.The company ended 2024 with $8.5 million in cash and cash equivalents.Operating expenses are also expected to reduce over 20% owing to reductions in research and development costs.On Stocktwits, retail sentiment continued to trend in the ‘extremely bearish’ territory while message volume jumped from ‘low’ to ‘high’ over the past 24 hours.<figure class="image"><img style="aspect-ratio:649/151;" src="https://news.stocktwits-cdn.com/Screenshot_2025_03_27_at_11_02_29_AM_png_72bc5e484f.webp" alt="TLSI's Sentiment Meter and Message Volume as of 11:30 a.m. ET on March 27, 2025 | Source: Stocktwits" width="649" height="151"><figcaption>TLSI's Sentiment Meter and Message Volume as of 11:30 a.m. ET on March 27, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed optimism about the company’s guidance.<stembedurl>https://stocktwits.com/FE123/message/609391420</stembedurl>Another highlighted the company’s growth in revenue.<stembedurl>https://stocktwits.com/FE123/message/609361644</stembedurl><a href="https://stocktwits.com/symbol/TLSI">TLSI shares</a> gained by over 12% this year but are down by over 40% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/new-fortress-energy-sells-jamaican-assets-to-excelerate-energy/chJ2EtuRbE4">New Fortress Energy Sells Jamaican Assets, Operations To Excelerate Energy For $1.06B: Stock Tumbles But Retail Cheers The Deal</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

The company reaffirmed its previous guidance for 2025 and said it expects sales growth of over 50% and its gross margin to exceed 87%, higher than the 86% reported for 2024. 

Current Price	$3.57
Prev Close	$3.63
Open	$3.75
Dividend Yield	0.00%
50-Day Moving Average	$4.40
Beta	0.57
Avg. Volume	144,835.49
PE Ratio	-2.80

52-Week High	$7.95
52-Week Low	$2.20
Market Capitalization	$223.52M
EPS (Annual)	-$1.84
Price to Book	34.07
Revenue Per Employee	$442,656.86

Feed

News

Sentiment

Earnings

Fundamentals

Info

TLSI Fundamentals